Mitochondrial dysfunction, which is often characterized by impaired fatty acid oxidation and energy production, can be mitigated by modulating the activity of mitochondrial carnitine/acylcarnitine carrier, CRAT, CROT, and other acetyltransferases structurally related to CRAT, aiming to restore normal lipid transport and energy metabolism in cells affected by mitochondrial diseases. The gene discussed is CRAT; the disease is inborn mitochondrial metabolism disorder.